Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma

被引：7

|

作者：

Lovestone, Simon ^{[1
]}

Manji, Husseini K. ^{[2
]}

机构：

[1] Janssen Cilag, High Wycombe, Bucks, England

[2] Johnson & Johnson, Titusville, NJ USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷 / 01期

关键词：

TAU PATHOLOGY; HYPOTHESIS;

D O I：

10.1002/cpt.1685

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：79 / 81

页数：3

相关论文

共 50 条

[21] Infliximab is the drug we have been waiting for in Crohn's disease
Rutgeerts, P
INFLAMMATORY BOWEL DISEASES, 2000, 6 (02) : 132 - 136
[22] The pink Viagra story - We have the drug, but what's the disease?
Tiefer, L
RADICAL PHILOSOPHY, 2003, (121): : 2 - 5
[23] Alzheimer's disease: Have we opened the Golden Gate to disease-modifying therapy?
Isaacs, Jeremy D.
CEREBRAL CIRCULATION-COGNITION AND BEHAVIOR, 2024, 6
[24] Disease-modifying therapies in Alzheimer's disease -: How far have we come?
Huell, Michael
Berger, Mathias
Heneka, Michael
DRUGS, 2006, 66 (16) : 2075 - 2093
[25] PERSONAL VIEW Have you heard the one about the man with Alzheimer's disease?
Behrman, Sophie
BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
[26] Do we have a treatment for Alzheimer disease? Yes
Gauthier, S
ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 738 - 739
[27] Inflammation in Alzheimer's disease: a view from the periphery - Commentary
Raine, CS
NEUROBIOLOGY OF AGING, 2000, 21 (03) : 437 - 440
[28] A reductionist view of Alzheimer's disease
Lansbury, PT
ACCOUNTS OF CHEMICAL RESEARCH, 1996, 29 (07) : 317 - 321
[29] What have we learned about cerebral amyloid from transgenic animal models of Alzheimer's disease?
Jucker, M
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2005, 31 (02) : 216 - 217
[30] A Mitocentric View of Alzheimer's Disease
Hu, Hao
Tan, Chen-Chen
Tan, Lan
Yu, Jin-Tai
MOLECULAR NEUROBIOLOGY, 2017, 54 (08) : 6046 - 6060

← 1 2 3 4 5 →